Table 3.

Options for ARV prophylaxis in HIV-infected women who do not require ARV treatment for their own health and infants, in Burkina Faso

Option A: AZT prenatal to mother	Option B: Maternal prophylaxis by three ARVs
Mother From the 14th week of pregnancy: AZT 300 mg x 2/day at the start of labor: NVP 200 mg as single dose; during labor and delivery: AZT+3TC 300/150 mg for 7 days after delivery: AZT+3TC 300/150 mg x 2/day	Mother Association of three ARVs from the 14th week of pregnancy and up to one week after the end of exposure to breast milk 1st intention: AZT (300 mg x 2/day) +3TC (150 mg x 2/day) + EFV (600 mg/day in a single dose) 2nd intention: AZT (300 mg x 2/day) +3TC (150 mg x 2/day) + LPV/r*(400/100 mg x 2/day) or AZT (300 mg x 2/day) +3TC (150 mg x 2/day) + ABC (300 mg x 2/day) Or TDF (300 mg/day) +3TC (150 mg x 2/day) + EFV (600 mg/day) or TDF (300 mg/day) + FTC (200 mg/day) + EFV (600 mg/day single dose)
Nursing infant 1st intention: Daily administration of NVP 4 mg/kg once daily from birth to up to one week after discontinuation of breastfeeding 2nd intention: AZT 4 mg/kg x 2/day up to one week after breastfeeding stopped Infant who is not breastfed 1st intention: NVP 4 mg/kg/day for 6 weeks 2nd intention: AZT 4 mg/kg x 2/day for 6 weeks	Nursing infant Daily administration 1st intention: NVP 4 mg/kg/day for 6 weeks 2nd intention: AZT 4 mg/kg x 2/day for 6 weeks Infant who is not breastfed Daily administration 1st intention: NVP 4 mg/kg/day for 6 weeks 2nd intention: AZT 4 mg/kg x 2/day for 6 weeks

Abbreviations: 3TC, Lamivudine; AZT, Zidovudine; ARV, Antiretroviral; NVP, Nevirapine; EFV, Efavirenz; TDF, Tenofovir; FTC, Emtricitabine.